Mutual of America Capital Management LLC Lowers Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

Mutual of America Capital Management LLC lessened its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 49.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,270 shares of the company’s stock after selling 25,071 shares during the period. Mutual of America Capital Management LLC’s holdings in Vaxcyte were worth $2,069,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of PCVX. Janus Henderson Group PLC grew its holdings in Vaxcyte by 23.1% in the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock valued at $1,247,954,000 after purchasing an additional 2,052,989 shares during the period. RA Capital Management L.P. grew its stake in Vaxcyte by 5.9% in the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock valued at $992,914,000 after acquiring an additional 485,436 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Vaxcyte by 47.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock worth $148,075,000 after acquiring an additional 419,600 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Vaxcyte during the third quarter worth $41,114,000. Finally, Franklin Resources Inc. lifted its holdings in Vaxcyte by 13.2% during the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock valued at $315,162,000 after purchasing an additional 324,560 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Trading Down 4.9 %

Shares of NASDAQ PCVX opened at $71.18 on Friday. The stock has a market cap of $9.17 billion, a PE ratio of -15.47 and a beta of 1.02. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The company has a 50-day moving average of $83.33 and a 200 day moving average of $94.51.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.14. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PCVX. Guggenheim reissued a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group initiated coverage on Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price objective for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $147.50.

Insiders Place Their Bets

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the transaction, the director now directly owns 7,175 shares of the company’s stock, valued at $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jim Wassil sold 8,000 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at approximately $17,208,443.70. This trade represents a 3.74 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 56,616 shares of company stock valued at $4,768,521. Insiders own 3.10% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.